NO20022886D0 - Nye lipopeptider som antibakterielle midler - Google Patents

Nye lipopeptider som antibakterielle midler

Info

Publication number
NO20022886D0
NO20022886D0 NO20022886A NO20022886A NO20022886D0 NO 20022886 D0 NO20022886 D0 NO 20022886D0 NO 20022886 A NO20022886 A NO 20022886A NO 20022886 A NO20022886 A NO 20022886A NO 20022886 D0 NO20022886 D0 NO 20022886D0
Authority
NO
Norway
Prior art keywords
antibacterial agents
new lipopeptides
lipopeptides
new
antibacterial
Prior art date
Application number
NO20022886A
Other languages
English (en)
Other versions
NO20022886L (no
Inventor
Jason Hill
Ian Parr
Michael Morytko
Jim Siedlecki
Xiang Yang Yu
Jared Silverman
Dennis Keith
John Finn
Dale Christensen
Tsvetelina Lazarova
Alan D Watson
Yan Zhang
Original Assignee
Cubist Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cubist Pharm Inc filed Critical Cubist Pharm Inc
Publication of NO20022886D0 publication Critical patent/NO20022886D0/no
Publication of NO20022886L publication Critical patent/NO20022886L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20022886A 1999-12-15 2002-06-17 Nye lipopeptider som antibakterielle midler NO20022886L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17094599P 1999-12-15 1999-12-15
PCT/US2000/034051 WO2001044271A2 (en) 1999-12-15 2000-12-15 Daptomycin analogs and their use as antibacterial agents

Publications (2)

Publication Number Publication Date
NO20022886D0 true NO20022886D0 (no) 2002-06-17
NO20022886L NO20022886L (no) 2002-08-02

Family

ID=22621920

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022886A NO20022886L (no) 1999-12-15 2002-06-17 Nye lipopeptider som antibakterielle midler

Country Status (13)

Country Link
US (1) US6794490B2 (no)
EP (1) EP1240182A2 (no)
JP (1) JP2003517003A (no)
KR (1) KR20020063230A (no)
CN (1) CN1423655A (no)
AU (1) AU784942B2 (no)
BR (1) BR0017028A (no)
CA (1) CA2394313A1 (no)
IL (1) IL150224A0 (no)
MX (1) MXPA02006028A (no)
NO (1) NO20022886L (no)
WO (1) WO2001044271A2 (no)
ZA (1) ZA200205113B (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001044274A1 (en) * 1999-12-15 2001-06-21 Cubist Pharmaceuticals, Inc. Lipopeptides as antibacterial agents
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
CA2301336A1 (en) * 2000-03-17 2001-09-17 Michael T. Kelly Topical treatment of rosacea
KR20090122469A (ko) 2000-12-18 2009-11-30 큐비스트 파마슈티컬즈 인코포레이티드 정제된 리포펩티드의 제조 방법
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
EP1932853A1 (en) 2001-08-06 2008-06-18 Cubist Pharmaceutical Inc. Novel depsipeptides and process for preparing same
IL160171A0 (en) 2001-08-06 2004-07-25 Cubist Pharm Inc Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US6767718B2 (en) 2002-05-10 2004-07-27 Biosource Pharm, Inc. Lipodepsipeptide antibiotics and methods of preparation
CA2490062A1 (en) * 2002-05-23 2003-12-04 Activbiotics, Inc. Methods of treating bacterial infections and diseases associated therewith
US20090149453A1 (en) * 2002-05-23 2009-06-11 Activbiotics Pharma Llc Methods and compositions for treating bacterial infections and diseases associated therewith
US20040077533A1 (en) * 2002-05-23 2004-04-22 Sayada Chalom B. Methods and compositions for treating bacterial infections and diseases associated therewith
US7317001B2 (en) 2002-06-06 2008-01-08 Oscient Pharmaceuticals Corporation Use of ramoplanin to treat diseases associated with the use of antibiotics
IL150907A (en) * 2002-07-25 2007-07-04 Stephan Cherkez Process for the preparation of stable amorphous calcium pseudomonate
CA2529125A1 (en) * 2003-06-19 2004-12-23 Yeda Research & Development Co. Ltd. Antimicrobial and anticancer lipopeptides
EP1675548A4 (en) * 2003-09-25 2008-08-13 Activbiotics Inc RIFALAZIL FORMULATIONS
EP1701733B1 (en) * 2003-12-30 2008-04-02 Bioactive Polymers AB Surface protection of exposed biological tissues
SE0303588D0 (sv) 2003-12-30 2003-12-30 Bioactive Polymers Ab C O Lund Surface protection of exposed biological tissues
WO2005089239A2 (en) 2004-03-13 2005-09-29 Cluster Resources, Inc. System and method of providing a self-optimizing reservation in space of compute resources
US8782654B2 (en) 2004-03-13 2014-07-15 Adaptive Computing Enterprises, Inc. Co-allocating a reservation spanning different compute resources types
US20070266388A1 (en) 2004-06-18 2007-11-15 Cluster Resources, Inc. System and method for providing advanced reservations in a compute environment
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
US8176490B1 (en) 2004-08-20 2012-05-08 Adaptive Computing Enterprises, Inc. System and method of interfacing a workload manager and scheduler with an identity manager
US8271980B2 (en) 2004-11-08 2012-09-18 Adaptive Computing Enterprises, Inc. System and method of providing system jobs within a compute environment
CA2587848A1 (en) * 2004-11-12 2006-10-19 Cubist Pharmaceuticals, Inc. Antiinfective lipopeptides
US20080051326A1 (en) * 2004-11-12 2008-02-28 Alexander Dylan C Antiinfective Lipopeptides
EP1860943A4 (en) * 2005-03-10 2008-06-18 Smithkline Beecham Corp NOVEL PROCEDURE
US8863143B2 (en) 2006-03-16 2014-10-14 Adaptive Computing Enterprises, Inc. System and method for managing a hybrid compute environment
US9231886B2 (en) 2005-03-16 2016-01-05 Adaptive Computing Enterprises, Inc. Simple integration of an on-demand compute environment
ES2614751T3 (es) 2005-04-07 2017-06-01 Iii Holdings 12, Llc Acceso bajo demanda a recursos informáticos
US8968781B2 (en) * 2005-04-29 2015-03-03 Cubist Pharmaceuticals, Inc. Therapeutic compositions
EP2018864A1 (en) 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
US8041773B2 (en) 2007-09-24 2011-10-18 The Research Foundation Of State University Of New York Automatic clustering for self-organizing grids
BRPI0923567A2 (pt) * 2008-12-22 2016-09-27 Cubist Pharm Inc agentes antibactericidas novos para o tratamento de infecções gram positivas
US8343912B2 (en) 2008-12-23 2013-01-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
US10877695B2 (en) 2009-10-30 2020-12-29 Iii Holdings 2, Llc Memcached server functionality in a cluster of data processing nodes
US11720290B2 (en) 2009-10-30 2023-08-08 Iii Holdings 2, Llc Memcached server functionality in a cluster of data processing nodes
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012011917A1 (en) * 2010-07-23 2012-01-26 Activbiotics Pharma, Llc Administration of rifalazil to immunocompromised patients
KR20140037877A (ko) * 2011-05-26 2014-03-27 큐비스트 파마슈티컬즈 인코포레이티드 Cb-183,315 조성물 및 관련 방법
EP3384938A1 (en) 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013059610A1 (en) 2011-10-20 2013-04-25 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
AU2013243951A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
WO2013151666A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of biologics and proteins associated with human disease
JP7041628B2 (ja) 2015-11-10 2022-03-24 ビステラ， インコーポレイテッド リポ多糖に特異的に結合する抗体分子－薬物コンジュゲートおよびその使用
US10358463B2 (en) * 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
EP3571223A1 (en) 2017-01-18 2019-11-27 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
JP7206222B2 (ja) * 2017-06-23 2023-01-17 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ－１のアンタゴニストとして作用する免疫調節剤
EP4126064A1 (en) 2020-04-03 2023-02-08 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399067A (en) 1982-05-21 1983-08-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
USRE32310E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
USRE32311E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
IL68700A0 (en) * 1982-05-21 1983-09-30 Lilly Co Eli Improvements relating to a-21978c cyclic peptide derivatives and their production
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
US4396543A (en) 1982-05-21 1983-08-02 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
EP0460882B1 (en) 1990-06-07 1996-07-24 Eli Lilly And Company Lipopeptide deacylase
DE4411025A1 (de) 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
KR100545506B1 (ko) 1996-03-08 2006-10-04 아스테라스 세이야쿠 가부시키가이샤 환상 리포펩티드 물질의 탈아실화 방법
DE19807972A1 (de) 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung

Also Published As

Publication number Publication date
AU3264001A (en) 2001-06-25
CN1423655A (zh) 2003-06-11
AU784942B2 (en) 2006-08-03
EP1240182A2 (en) 2002-09-18
WO2001044271A3 (en) 2002-03-07
WO2001044271A2 (en) 2001-06-21
US6794490B2 (en) 2004-09-21
BR0017028A (pt) 2003-01-07
NO20022886L (no) 2002-08-02
ZA200205113B (en) 2003-11-26
MXPA02006028A (es) 2004-08-23
US20020058785A1 (en) 2002-05-16
KR20020063230A (ko) 2002-08-01
CA2394313A1 (en) 2001-06-21
IL150224A0 (en) 2002-12-01
JP2003517003A (ja) 2003-05-20

Similar Documents

Publication Publication Date Title
NO20022886L (no) Nye lipopeptider som antibakterielle midler
NO20022888D0 (no) Nye lipopeptider som antibakterielle midler
NO20022887D0 (no) Lipopeptider som antibakterielle midler
NO20031001D0 (no) Polyarylkarboksamider nyttige som lipidsenkende midler
NO20021116L (no) Nye sammensetninger
NO20011738D0 (no) Heterocyclylaminometyloksazolidinoner som antibakterielle midler
NO20026195D0 (no) Substituerte-triazolopyrimidiner som anticancer midler
NO20014412L (no) Forbindelser nyttige som anti-inflammatoriske midler
NO20013671L (no) Substituerte bisycliske derivater nyttige som anticancer midler
NO20042955L (no) Substituerte fenylaftalener som estrogene midler
NO20015855L (no) Ny anvendelse av forbindelser som antibakterielle midler
NO20035193L (no) Nye pyrrolderivater som farmas degree ytiske midler
NO20022502D0 (no) Nye antidiabetiske midler
NO20021329L (no) Kinaseinhibitorer som terapeutiske midler
DK1326858T3 (da) Piperidinforbindelser som anti-allergiske midler
DK1028961T5 (da) Pleuromutilinderivater som antimikrobielle midler
NO20020810L (no) Nye fenylpiperaziner
NO20032272L (no) Bifenylkarboksamider nyttige som lipidsenkende midler
NO20015074L (no) Nye sammensetninger
NO20024745L (no) 2-hydroksymutilinkarbamat-derivater for antibakteriell anvendelse
NO20030100L (no) Pleuromutilinderivater som har antibakteriell aktivitet
DK1246810T3 (da) Piperidinyloxy- og pyrrolidinyloxyphenyloxazolidinoner som antibakterielle midler
DK1181288T3 (da) Bicycliske oxazolidinoner som antibakterielle midler
NO20020621D0 (no) Antibakterielle midler
NO20021251D0 (no) Tienoisoksazolyl- og tienylpyrrazolyl-fenoksysubstituerte propylderivater anvendelige som D4antagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application